APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals – a cross-sectional observational study

Abstract

BackgroundCerebrospinal fluid (CSF) biomarkers Aβ1-42, t-tau and p-tau have a characteristic pattern in Alzheimer’s Disease (AD). Their roles in HIV-associated neurocognitive disorder (HAND) remains unclear.MethodsAdults with chronic treated HIV disease were recruited (n = 43, aged 56.7 ± 7.9; 32% aged 60+; median HIV duration 20 years, >95% plasma and CSF HIV RNA <50 cp/mL, on cART for a median 24 months). All underwent standard neuropsychological testing (61% had HAND), APOE genotyping (30.9% carried APOE ε4 and 7.1% were ε4 homozygotes) and a lumbar puncture. Concentrations of Aβ1-42, t-tau and p-tau were assessed in the CSF using commercial ELISAs. Current neurocognitive status was defined using the continuous Global Deficit Score, which grades impairment in clinically relevant categories. History of HAND was recorded. Univariate correlations informed multivariate models, which were corrected for nadir CD4-T cell counts and HIV duration.ResultsCarriage of APOE ε4 predicted markedly lower levels of CSF Aβ1-42 in univariate (r = -.50; p = .001) and multivariate analyses (R2 = .25; p < .0003). Greater levels of neurocognitive impairment were associated with higher CSF levels of p-tau in univariate analyses (r = .32; p = .03) and multivariate analyses (R2 = .10; p = .03). AD risk prediction cut-offs incorporating all three CSF biomarkers suggested that 12.5% of participants had a high risk for AD. Having a CSF-AD like profile was more frequent in those with current (p = .05) and past HIV-associated dementia (p = .03).ConclusionsSimilarly to larger studies, APOE ε4 genotype was not directly associated with HAND, but moderated CSF levels of Aβ1-42 in a minority of participants. In the majority of participants, increased CSF p-tau levels were associated with current neurocognitive impairment. Combined CSF biomarker risk for AD in the current HIV+ sample is more than 10 times greater than in the Australian population of the same age. Larger prospective studies are warranted.Electronic supplementary materialThe online version of this article (doi:10.1186/s12883-015-0298-0) contains supplementary material, which is available to authorized users.

Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals

“…Our results show that CSF IFNα levels negatively correlate with multiple measures of neurocognitive function, including a composite score that reflects global performance. These correlations may have been driven by participants with more significant impairment (a GDS of ≥1.5 as suggested by other studies) (Cysique et al , 2015). Participants with GDS ≥1.5 had significantly higher CSF IFNα levels.…”

Caffeine Blocks HIV-1 Tat-Induced Amyloid Beta Production and Tau Phosphorylation

“…Indeed, endolysosomes have been implicated in the pathogenesis of sporadic AD (Tate and Mathews, 2006; Boland et al, 2008) and HAND (Gelman et al, 2005; Spector and Zhou, 2008; Zhou and Spector, 2008; Cysique et al, 2015). Neurons, as long-lived post-mitotic cells, are especially vulnerable to perturbations of endolysosome pH and by maintaining an acidic environment endolysosomes are able to control the integrity of quality of critical proteins (Nixon and Cataldo, 1995; Bonaldo and Sandri, 2013).…”

Differentiating HIV-Associated Neurocognitive Disorders From Alzheimer’s Disease: an Emerging Issue in Geriatric NeuroHIV

“…[42] In another study ApoE ε4 was found to moderate the expression of amyloid in HAND subjects, although the authors failed to find a direct association between ApoE ε4 carrier status and HAND. [43] Similarly, autopsy findings showed that the presence of diffuse amyloid plaques was associated with HAND among ApoE ε4 carriers, but not in non-ε4 carriers, suggesting that ApoE isoforms differently moderate the association between amyloid aggregation and HAND. [44]…”